Preexposure prophylaxis for HIV prevention

Current HIV/AIDS Reports

Volumn 8, Issue 2, 2011, Pages 94-103

  Kelesidis, Theodoros ^a   Landovitz, Raphael J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretrovirals; HIV; Preexposure prophylaxis

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO; TENOFOVIR; TENOFOVIR DISOPROXIL;

ARTICLE; BONE DENSITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY INJURY; MATHEMATICAL MODEL; PATIENT COMPLIANCE; PROPHYLAXIS; SIDE EFFECT; VIRUS LOAD;

ANTI-HIV AGENTS; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 79957484785     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-011-0078-4     Document Type: Article

References (56)

1. RJ Landovitz JS Currier 2009 Clinical practice. Postexposure prophylaxis for HIV infection N Engl J Med 361 18 1768 1775 19864675 10.1056/NEJMcp0904189 1:CAS:528:DC%2BD1MXhtlajsb%2FL
2. RC Bailey S Moses CB Parker K Agot I Maclean JN Krieger, et al. 2007 Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial Lancet 369 9562 643 656 17321310 10.1016/S0140-6736(07)60312-2 A randomized trial of 2784 young men age 18 to 24 in Kisumu, Kenya demonstrated a 53% reduction in HIV acquisition among men who were randomized to the circumcision intervention compared with men randomized to the nonsurgical arm. (Pubitemid 46281312)
3. KQ Abdool SS Abdool Karim JA Frohlich AC Grobler C Baxter LE Mansoor, et al. 2010 Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science 329 5996 1168 1174 10.1126/science.1193748 A randomized trial of 889 women in South Africa demonstrated a 39% reduction in HIV acquisition among women who were randomized to a coitally-dependent regimen of 1% tenofovir gel compared to women randomized to a placebo arm, both when combined with intensive testing and risk reduction counseling.
4. SH Vermund DL Van 2011 HIV prevention in women: next steps Science 331 6015 284 21252332 10.1126/science.331.6015.284-a
5. JH Kim S Rerks-Ngarm JL Excler NL Michael 2010 HIV vaccines: lessons learned and the way forward Curr Opin HIV AIDS 5 5 428 434 20978385 10.1097/COH.0b013e32833d17ac
6. NS Padian A Buve J Balkus D Serwadda W Cates Jr 2008 Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward Lancet 372 9638 585 599 18687456 10.1016/S0140-6736(08)60885-5 1:CAS:528:DC%2BD1cXpvFKgsLk%3D
7. MS Cohen C Gay AD Kashuba S Blower L Paxton 2007 Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1 Ann Intern Med 146 8 591 601 17438318 (Pubitemid 351650540)
8. RM Grant JR Lama PL Anderson V McMahan AY Liu L Vargas, et al. 2010 Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men N Engl J Med 363 27 2587 2599 21091279 10.1056/NEJMoa1011205 1:CAS:528: DC%2BC3MXit1ansg%3D%3D A randomized trial of 2499 MSM in South America, South Africa, Thailand, and the US demonstrated a 44% reduction in HIV acquisition among MSM randomized to a daily regimen of FTC/tenofovir compared to MSM randomized to a placebo treatment, both when combined with intensive testing and risk reduction counseling.
9. LA Paxton T Hope HW Jaffe 2007 Pre-exposure prophylaxis for HIV infection: what if it works? Lancet 370 9581 89 93 17617276 10.1016/S0140- 6736(07)61053-8 (Pubitemid 47033881)
10. K Borroto-Esoda JE Vela F Myrick AS Ray MD Miller 2006 In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine Antivir Ther 11 3 377 384 16759055 1:CAS:528:DC%2BD28XlvF2lurw%3D (Pubitemid 43823557)
11. JB Dumond RF Yeh KB Patterson AH Corbett BH Jung NL Rezk, et al. 2007 Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis AIDS 21 14 1899 1907 17721097 10.1097/QAD.0b013e328270385a 1:CAS:528:DC%2BD2sXpsFahsLg%3D (Pubitemid 47329766)
12. JB Dumond KB Patterson AL Pecha RE Werner E Andrews B Damle, et al. 2009 Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women J Acquir Immune Defic Syndr 51 5 546 553 19546811 10.1097/QAI.0b013e3181ae69c5
13. RM Grant 2010 Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis Clin Infect Dis 50 Suppl 3 S96 101 20397962 10.1086/651479
14. CJ Miller Q Li K Abel EY Kim ZM Ma S Wietgrefe, et al. 2005 Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus J Virol 79 14 9217 9227 15994816 10.1128/JVI.79.14.9217- 9227.2005 1:CAS:528:DC%2BD2MXmtFOjt70%3D (Pubitemid 40934833)
15. JG Garcia-Lerma ME Cong J Mitchell AS Youngpairoj Q Zheng S Masciotra, et al. 2010 Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection Sci Transl Med 2 14 14ra4 20371467 Macaque studies of rectal SHIV challenge demonstrated efficacy of intermittent dosing strategies comparable to continuous daily dosing, likely attributable to prolonged intracellular half-lives of tenofovir-DP and to a lesser extent FTC-DP. Dosing 1, 3, and 7 days prior to repeated SHIV challenge and re-dosing 2 hours after was about as effective for protection as continuous daily dosing.
16. MR Blum GE Chittick JA Begley J Zong 2007 Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers J Clin Pharmacol 47 6 751 759 17519400 10.1177/0091270007300951 1:CAS:528:DC%2BD2sXmvF2jtrw%3D (Pubitemid 46800418)
17. M Gandhi LZ Benet P Bacchetti A Kalinowski K Anastos AR Wolfe, et al. 2009 Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women J Acquir Immune Defic Syndr 50 5 482 491 19408353 10.1097/QAI.0b013e31819c3376 1:CAS:528:DC%2BD1MXjtlOhtrY%3D
18. J Volmink NL Siegfried L van der Merwe P Brocklehurst 2007 Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection Cochrane Database Syst Rev 1 CD003510 17253490
19. T Hawkins W Veikley RL St Claire B Guyer N Clark BP Kearney 2005 Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens J Acquir Immune Defic Syndr 39 4 406 411 16010161 10.1097/01.qai.0000167155.44980. e8 1:CAS:528:DC%2BD2MXmtVWqsrw%3D (Pubitemid 41003784)
20. BF Keele EE Giorgi JF Salazar-Gonzalez JM Decker KT Pham MG Salazar, et al. 2008 Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection Proc Natl Acad Sci USA 105 21 7552 7557 18490657 10.1073/pnas.0802203105 1:CAS:528:DC%2BD1cXmvFKksrg%3D (Pubitemid 351830056)
21. KK Van Rompay MB McChesney NL Aguirre KA Schmidt N Bischofberger ML Marthas 2001 Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection J Infect Dis 184 4 429 438 11471100 10.1086/322781 (Pubitemid 32718506)
22. Anton P, Cranston R, Carballo-Dieguez A, Kashuba A, Khanukhova E, Elliott J et al. RMP-02/MTN-006: A Phase 1 Placebo-controlled Trial of Rectally Applied 1% Vaginal TFV Gel with Comparison to Oral TDF [Abstract 34LB]. Presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA, February 27-March 2, 2011.
23. JG Garcia-Lerma RA Otten SH Qari E Jackson ME Cong S Masciotra, et al. 2008 Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir PLoS Med 5 2 e28 18254653 10.1371/journal.pmed.0050028 (Pubitemid 351317659)
24. AD Paltiel KA Freedberg CA Scott BR Schackman E Losina B Wang, et al. 2009 HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness Clin Infect Dis 48 6 806 815 19193111 10.1086/597095 A well-validated mathematical model of HIV dynamics demonstrated that while at current costs, Truvada-based PrEP was unlikely to be cost effective, efficacy levels of at least 60%, reduced drug costs, and targeting of treatment to young high-risk individuals had the potential to be cost-saving
25. KK Van Rompay BP Kearney JJ Sexton R Colon JR Lawson EJ Blackwood, et al. 2006 Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus J Acquir Immune Defic Syndr 43 1 6 14 16810108 10.1097/01.qai.0000224972.60339.7c (Pubitemid 44306481)
26. KK Van Rompay KA Schmidt JR Lawson R Singh N Bischofberger ML Marthas 2002 Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus J Infect Dis 186 10 1508 1513 12404171 10.1086/344360 (Pubitemid 35286123)
27. S Subbarao RA Otten A Ramos C Kim E Jackson M Monsour, et al. 2006 Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges J Infect Dis 194 7 904 911 16960777 10.1086/507306 1:CAS:528:DC%2BD28XhtFSgt7zO (Pubitemid 44454075)
28. PW Denton JD Estes Z Sun FA Othieno BL Wei AK Wege, et al. 2008 Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice PLoS Med 5 1 e16 18198941 10.1371/journal.pmed.0050016 (Pubitemid 351198263)
29. EM Connor RS Sperling R Gelber P Kiselev G Scott MJ O'Sullivan, et al. 1994 Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group N Engl J Med 331 18 1173 1180 7935654 10.1056/ NEJM199411033311801 1:STN:280:DyaK2M%2FitFGmuw%3D%3D (Pubitemid 24331334)
30. J Cohen 2005 HIV/AIDS. Prevention cocktails: combining tools to Stop HIV's spread Science 309 5737 1002 1005 16099959 10.1126/science.309.5737.1002 1:CAS:528:DC%2BD2MXotFSjtbw%3D (Pubitemid 41134439)
31. L Peterson D Taylor R Roddy G Belai P Phillips K Nanda, et al. 2007 Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial PLoS Clin Trials 2 5 e27 17525796 10.1371/journal.pctr.0020027 (Pubitemid 46851988)
32. AVAC (2011) PrEP clinical trials. Available at http://www.avac.org/ht/d/ sp/i/3507/pid/3507. accessed March 2, 2011.
33. UL Abbas RM Anderson JW Mellors 2006 Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings J Acquir Immune Defic Syndr 41 5 632 641 16652038 10.1097/01.qai.0000194234.31078. bf
34. DC Vissers HA Voeten NJ Nagelkerke JD Habbema SJ de Vlas 2008 The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study PLoS ONE 3 5 e2077 18461185 10.1371/journal.pone.0002077
35. N Prada B Davis P Jean-Pierre RM La FM Duh M Carrington, et al. 2008 Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course J Acquir Immune Defic Syndr 49 2 117 122 18769360 10.1097/QAI.0b013e3181869a9b 1:CAS:528: DC%2BD1cXhtFKmu7%2FM
36. KK Van Rompay MD Miller ML Marthas NA Margot PJ Dailey DR Canfield, et al. 2000 Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA J Virol 74 4 1767 1774 10644348 10.1128/JVI.74.4.1767-1774.2000 (Pubitemid 30434034)
37. V Supervie JG Garcia-Lerma W Heneine S Blower 2010 HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis Proc Natl Acad Sci USA 107 27 12381 12386 20616092 10.1073/pnas.1006061107 1:CAS:528: DC%2BC3cXovFGqu7g%3D
38. KH Mayer LA Maslankowski F Gai WM El-Sadr J Justman A Kwiecien, et al. 2006 Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women AIDS 20 4 543 551 16470118 10.1097/01.aids.0000210608.70762.c3 1:CAS:528:DC%2BD28Xht1Cmtb8%3D (Pubitemid 43731598)
39. Grant R, Lama J, Glidden D and iPrEx Study Team. Pre-exposure Chemoprophylaxis for Prevention of HIV among Trans-women and MSM: iPREx Study [Abstract 92]. Presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA, February 27-March 2, 2011.
40. th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA, February 27-March 2, 2011.
41. SS Abdool Karim C Baxter 2009 Antiretroviral prophylaxis for the prevention of HIV infection: future implementation challenges HIV Therapy 3 1 3 6 10.2217/17584310.3.1.3 1:CAS:528:DC%2BD1MXjs1WnsbY%3D
42. th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA, February 27-March 2, 2011.
43. th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA, February 27-March 2, 2011.
44. RM Grant MA Wainberg 2006 Chemoprophylaxis of HIV infection: moving forward with caution J Infect Dis 194 7 874 876 16960773 10.1086/507314 1:CAS:528:DC%2BD28XhtFSgt7%2FK (Pubitemid 44454071)
45. •• Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men. MMWR Morb Mortal Wkly Rep 2011;60(3):65-68. The CDC codifies preliminary clinical guidance for the deployment of PrEP to MSM as an HIV prevention strategy, recommending HIV testing every 2 to 3 months on treatment, dispensation of a maximum of 3 months of FTC/tenofovir at a time to ensure appropriate follow-up, and careful testing at baseline to rule-out undetected primary or acute HIV infection.
46. D Donnell JM Baeten J Kiarie KK Thomas W Stevens CR Cohen, et al. 2010 Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis Lancet 375 9731 2092 2098 20537376 10.1016/S0140-6736(10)60705-2
47. RS Veazey MS Springer PA Marx J Dufour PJ Klasse JP Moore 2005 Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor Nat Med 11 12 1293 1294 16273102 10.1038/nm1321 1:CAS:528:DC%2BD2MXht1yisrzL (Pubitemid 41752908)
48. KK Van Rompay CJ Berardi NL Aguirre N Bischofberger PS Lietman NC Pedersen, et al. 1998 Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection AIDS 12 9 F79 F83 9662190 10.1097/00002030-199809000-00001 (Pubitemid 28276962)
49. RS Veazey TJ Ketas J Dufour T Moroney-Rasmussen LC Green PJ Klasse, et al. 2010 Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor J Infect Dis 202 5 739 744 20629537 10.1086/655661 1:CAS:528:DC%2BC3cXhtFKjsr%2FF
50. UM Parikh C Dobard S Sharma ME Cong H Jia A Martin, et al. 2009 Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine J Virol 83 20 10358 10365 19656878 10.1128/JVI.01073-09 1:CAS:528: DC%2BD1MXhtlClsbjE
51. CC Tsai KE Follis A Sabo TW Beck RF Grant N Bischofberger, et al. 1995 Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine Science 270 5239 1197 1199 7502044 10.1126/science.270.5239.1197 1:CAS:528:DyaK2MXpsVyktLY%3D
52. M Cranage S Sharpe C Herrera A Cope M Dennis N Berry, et al. 2008 Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel PLoS Med 5 8 e157 18684007 10.1371/journal.pmed.0050157
53. RS Veazey PJ Klasse SM Schader Q Hu TJ Ketas M Lu, et al. 2005 Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion Nature 438 7064 99 102 16258536 10.1038/nature04055 1:CAS:528:DC%2BD2MXhtFOjurzN (Pubitemid 41599827)
54. T Hatziioannou Z Ambrose NP Chung M Piatak Jr F Yuan CM Trubey, et al. 2009 A macaque model of HIV-1 infection Proc Natl Acad Sci USA 106 11 4425 4429 19255423 10.1073/pnas.0812587106 1:CAS:528:DC%2BD1MXjslyhsLo%3D
55. RS Veazey PJ Klasse TJ Ketas JD Reeves M Piatak Jr K Kunstman, et al. 2003 Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection J Exp Med 198 10 1551 1562 14623909 10.1084/jem.20031266 1:CAS:528:DC%2BD3sXptFOgsLw%3D (Pubitemid 37467169)
56. PW Denton JF Krisko DA Powell M Mathias YT Kwak F Martinez-Torres, et al. 2010 Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice PLoS ONE 5 1 e8829 20098623 10.1371/journal.pone.0008829